Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

RCT (n=243) found tocilizumab was not effective for preventing intubation or death in moderately ill hospitalised patients with Covid-19 (HR for intubation/death as compared with placebo = 0.83; 95% CI, 0.38-1.81; p=0.64, and for disease worsening, HR =1.11; 0.59-2.10; p=0.73).

SPS commentary:

JAMA Internal Medicine featured three studies exploring the use of tocilizumab in COVID-19 pneumonia; the two RCTs did not show clear evidence of efficacy, in contrast to the observational study, and overall, it was considered that these findings do not support the routine use of tocilizumab for COVID-19 in most settings.

New England Journal of Medicine

Resource links:

JAMA Internal Medicine editorial